Clicky

Affimed Therapeutics B.V.(AFMD)

Description: Affimed Therapeutics B.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate includes AFM13, a natural killer cell bispecific antibody (TandAb) that has completed a Phase I clinical trial for the treatment of certain CD30-positive (CD30+) B- and T-cell malignancies, including hodgkin lymphoma. The company's product candidates also comprise AFM11, a T-cell TandAb for the treatment of certain CD19+ B-cell malignancies, including non-hodgkin lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor variant III for solid tumors, as well as for patients with glioblastoma, hormone refractory prostate cancer, and head and neck cancer. Affimed Therapeutics B.V. has license agreements with Amphivena Therapeutics, Inc. to develop a product candidate for hematologic malignancies; and Xoma Ireland Limited to conduct research on immunoglobulins. The company was founded in 2000 and is headquartered in Heidelberg, Germany.


Keywords: Medicine Cancer Biopharmaceutical Solid Tumors Monoclonal Antibodies Prostate Cancer Clinical Development Lymphoma Immunotherapies Glioblastoma Blastoma Head And Neck Cancer Hematologic Malignancies Chronic Lymphocytic Leukemia Epidermal Growth Factor Receptor Natural Killer Cell Tumors Of The Hematopoietic And Lymphoid Tissues CD19 Lymphocytic Leukemia Non Hodgkin Lymphoma Hodgkin Lymphoma Entospletinib Acute Lymphocytic Leukemia Cd30

Home Page: www.affimed.com

AFMD Technical Analysis

Technologiepark
Heidelberg, 69120
Germany
Phone: 49 6221 6743 60


Officers

Name Title
Dr. Adi Hoess CEO, MD & Member of Management Board
Mr. Angus W. Smith CFO & Member of Management Board
Dr. Wolfgang Fischer MD, COO & Member of Management Board
Ms. Denise Mueller Chief Bus. Officer & Member of Management Board
Dr. Andreas Harstrick M.D. Chief Medical Officer & Member of Management Board
Dr. Arndt J. G. Schottelius M.D., Ph.D. Chief Scientific Officer & Member of Management Board
Prof. Melvyn Little Founder & Consultant
Mr. Michael Wolf Head of Fin. & Admin.
Mr. Alexander Fudukidis Head of Investor Relations
Dr. Uwe Reusch Head of Cell Culture

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.9232
Price-to-Sales TTM: 3.7958
IPO Date: 2014-09-12
Fiscal Year End: December
Full Time Employees: 197
Back to stocks